These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 24981617)

  • 1. Automation and robotics in ADME screening.
    Saunders KC
    Drug Discov Today Technol; 2004 Dec; 1(4):373-80. PubMed ID: 24981617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HTS Technologies--IBC Informa Conference.
    Kubinyi H
    IDrugs; 2001 Feb; 4(2):168-73. PubMed ID: 16032477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico pharmacology for a multidisciplinary drug discovery process.
    Ortega SS; Cara LC; Salvador MK
    Drug Metabol Drug Interact; 2012; 27(4):199-207. PubMed ID: 23152402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel trends in high-throughput screening.
    Mayr LM; Bojanic D
    Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can the Internet help to meet the challenges in ADME and e-ADME?
    Van de Waterbeemd H; De Groot M
    SAR QSAR Environ Res; 2002; 13(3-4):391-401. PubMed ID: 12184380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Automated high throughput ADME assays for metabolic stability and cytochrome P450 inhibition profiling of combinatorial libraries.
    Jenkins KM; Angeles R; Quintos MT; Xu R; Kassel DB; Rourick RA
    J Pharm Biomed Anal; 2004 Mar; 34(5):989-1004. PubMed ID: 15019033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro ADME profiling using high-throughput rapidfire mass spectrometry: cytochrome p450 inhibition and metabolic stability assays.
    Wu X; Wang J; Tan L; Bui J; Gjerstad E; McMillan K; Zhang W
    J Biomol Screen; 2012 Jul; 17(6):761-72. PubMed ID: 22460176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-throughput screening for lead optimization: a rational approach.
    Bajpai M; Adkison KK
    Curr Opin Drug Discov Devel; 2000 Jan; 3(1):63-71. PubMed ID: 19649839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Automated sample preparation and LC-MS for high-throughput ADME quantification.
    O'Connor D
    Curr Opin Drug Discov Devel; 2002 Jan; 5(1):52-8. PubMed ID: 11865673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput screening: update on practices and success.
    Fox S; Farr-Jones S; Sopchak L; Boggs A; Nicely HW; Khoury R; Biros M
    J Biomol Screen; 2006 Oct; 11(7):864-9. PubMed ID: 16973922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applications of high-throughput ADME in drug discovery.
    Kassel DB
    Curr Opin Chem Biol; 2004 Jun; 8(3):339-45. PubMed ID: 15183334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of a rapid and integrated analysis system (RIAS) as a high-throughput processing tool for in vitro ADME samples by liquid chromatography/tandem mass spectrometry.
    Luippold AH; Arnhold T; Jörg W; Krüger B; Süssmuth RD
    J Biomol Screen; 2011 Mar; 16(3):370-7. PubMed ID: 21335598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An integrated bioanalytical platform for supporting high-throughput serum protein binding screening.
    Zhang J; Shou WZ; Vath M; Kieltyka K; Maloney J; Elvebak L; Stewart J; Herbst J; Weller HN
    Rapid Commun Mass Spectrom; 2010 Dec; 24(24):3593-601. PubMed ID: 21080511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status and future directions of high-throughput ADME screening in drug discovery.
    Shou WZ
    J Pharm Anal; 2020 Jun; 10(3):201-208. PubMed ID: 32612866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of a high-throughput absorption, distribution, metabolism, and excretion (ADME) system and results for 60 literature compounds.
    Yan Z; Lu C; Wu JT; Elvebak L; Brockman A
    Rapid Commun Mass Spectrom; 2005; 19(9):1191-9. PubMed ID: 15818724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent development in high-throughput bioanalytical support for in vitro ADMET profiling.
    Shou WZ; Zhang J
    Expert Opin Drug Metab Toxicol; 2010 Mar; 6(3):321-36. PubMed ID: 20163321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High content screening: seeing is believing.
    Zanella F; Lorens JB; Link W
    Trends Biotechnol; 2010 May; 28(5):237-45. PubMed ID: 20346526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug selection in early drug development: screening for acceptable pharmacokinetic properties using combined in vitro and computational approaches.
    Sinko PJ
    Curr Opin Drug Discov Devel; 1999 Jan; 2(1):42-8. PubMed ID: 19649916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High performance affinity chromatography (HPAC) as a high-throughput screening tool in drug discovery to study drug-plasma protein interactions.
    Vuignier K; Guillarme D; Veuthey JL; Carrupt PA; Schappler J
    J Pharm Biomed Anal; 2013 Feb; 74():205-12. PubMed ID: 23245252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of an ADME and drug-drug interactions knowledge database for the acceleration of drug discovery and development.
    Petitet F; Barberan O; Dubus E; Ijjaali I; Donlan M; Ollivier S; Michel A
    Expert Opin Drug Discov; 2006 Dec; 1(7):737-51. PubMed ID: 23495997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.